Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179170 | 1.00 | CHRM5 (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL20292058 | 1.00 | CHRM5 (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL7008410 | 0.94 | MEN1 (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL4599754 | 0.92 | MEN1 (0.45) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL9786152 | 0.78 | ALDH1A1 (0.37) | MEN1KMT2APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL5802520 | 0.78 | ALDH1A1 (0.37) | MEN1KMT2APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL12503556 | 0.77 | RAB9A (0.41) | MEN1KMT2ACYP2D6CYP2C19POLB | |
| SCHEMBL8204301 | 0.77 | ALDH1A1 (0.36) | MEN1KMT2APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL7012221 | 0.77 | MAPT (0.34) | MEN1KMT2APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL7014181 | 0.74 | MAPT (0.38) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | claimed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | claimed |
| CN-115867282-B | 5-Amino-8- (4-pyridyl) - [1,2,4] triazolo [4,3-C ] pyrimidin-3-one compounds for anticancer use | 奈克斯拉制药英国有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| CN-115867282-A | 5-amino-8- (4-pyridyl) - [1,2,4] triazolo [4,3-C ] pyrimidin-3-one compounds for anticancer | 赫普泰雅治疗有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4126872-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | Heptares Therapeutics Limited (GB) | 2023-02-08 | — | — | EP | disclosed |
| US-11161863-B2 | Chiral catalyst and method for asymmetric reduction of an imine | DALHOUSIE UNIVERSITY (CA) | 2021-11-02 | — | — | US | disclosed |
| WO-2021191378-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191378-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | disclosed |
| US-7157451-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1165510-B1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| US-6706720-B2 | TREATMENT OF ARRHYTHMIA; INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | PEDESTRIAN CONCEPTS LLC | 2003-01-30 | — | — | US | disclosed |
| EP-1237891-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1165510-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2001040231-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNH2, KCNH1 | CHRM5 1262/4885CHRM3 1966/4885CHRM2 2956/4885 |
| US-11161863-B2 | Chiral catalyst and method for asymmetric reduction of an imine | C1R, C5, C1S | CHRM5 443/4885CHRM3 405/4885CHRM2 98/4885 |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ADORA2A, ADORA1, ADORA3 | CHRM5 307/4885CHRM3 774/4885CHRM2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.